FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used to treat cancer. Methods, pharmaceutical compositions, uses, an article, a product and a therapeutic combination of the invention relate to the treatment of cancer by the administration of a phosphoinositide-3-kinase (PI3K) inhibitor, GDC-0032 and a chemotherapeutic agent selected from fulvestrant and letrozole.
EFFECT: use of inventions provides the enhanced antitumor activity due to the synergistic effect of the combination.
39 cl, 5 tbl, 44 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
